SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
SAN FRANCISCO, May 07, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in Solid Biosciences, Inc. (NASDAQ:SLDB) of the May 29, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
